Bone Health and Fracture Risk in Parkinson's Disease

Parkinson’s disease (PD) is characterised not only by progressive neurodegeneration but also by systemic skeletal deterioration that substantially elevates fracture risk. Reduced mobility, postural instability and bradykinesia increase the likelihood of falls, while disease‐related metabolic alterations and long‐term dopaminergic therapy may compromise bone remodelling. An imbalance between osteoclast-mediated resorption and osteoblast-driven formation leads to low bone mineral density (BMD), particularly at the hip, spine and distal radius. Epidemiological data indicate a two- to threefold rise in overall fracture incidence among PD patients compared with age- and sex-matched controls. This heightened vulnerability carries global health implications, as fractures in this population are associated with prolonged hospital stays, increased morbidity and accelerated loss of independence. Early assessment of bone health, fall‐prevention strategies and targeted antiosteoporotic interventions are vital components of comprehensive PD management.

Research from Nature Portfolio

Recent clinical evaluation of surgical fixation in PD patients with upper extremity fractures reveals concerning rates of treatment failure. In a retrospective series of forty operated cases, nearly 41 percent of fractures exhibited fixation failure within three months, often necessitating reoperation or prolonged immobilisation. Humeral fractures demonstrated the highest complication rates and longest hospital stays, reflecting the interplay of reduced BMD, muscle rigidity and comorbidities. These findings underscore the importance of optimising bone strength pre-operatively, employing robust fixation techniques and integrating multidisciplinary postoperative rehabilitation to improve outcomes and reduce readmissions in this vulnerable cohort.

Bone Health and Fracture Risk in Parkinson's Disease publication trend

The graph below shows the total number of articles in bone health and fracture risk in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Bone mineral density (BMD): Quantitative measure of mineral content per unit area of bone, used to assess fracture risk.

Osteoclast: Multinucleated cell responsible for bone matrix resorption during normal remodelling and in pathological states.

Parkin: Ubiquitin E3 ligase whose deficiency in PD is linked to enhanced osteoclast activity and inflammatory bone erosion.

FRAX: Clinical tool combining risk factors and BMD to estimate individual ten-year probability of major osteoporotic fractures.

Osteoporosis: Systemic skeletal disorder characterised by low bone mass and microarchitectural deterioration, increasing susceptibility to fracture.

References

1. Dysfunction in parkin aggravates inflammatory bone erosion by reinforcing osteoclast activity. Cell & Bioscience (2023).
2. Parkinson’s Disease and Risk of Fracture: A Meta-Analysis of Prospective Cohort Studies. PLOS ONE (2014).
3. A service development study of the assessment and management of fracture risk in Parkinson’s disease. Journal of Neurology (2014).
4. Bone Mineral Density and Risk of Osteoporotic Fractures in Women with Parkinson’s Disease. Journal of Osteoporosis (2020).
5. Surgical outcome of upper extremity fractures in patients with Parkinson’s disease. Scientific Reports (2020).